Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2016, Article ID 7596482, 14 pages
http://dx.doi.org/10.1155/2016/7596482
Research Article

Blood Plasma of Patients with Parkinson’s Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity

1Department of Neurobiology, Xuanwu Hospital of Capital Medical University, Beijing, China
2Department of Human Anatomy, School of Basic Medical Sciences, Beihua University, Jilin, China
3Center of Parkinson’s Disease, Beijing Institute for Brain Disorders, Beijing, China
4Beijing Key Laboratory for Parkinson’s Disease, Beijing, China

Received 23 June 2016; Revised 16 September 2016; Accepted 9 October 2016

Academic Editor: Hélio Teive

Copyright © 2016 Peng Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. S. Pollanen, D. W. Dickson, and C. Bergeron, “Pathology and biology of the lewy body,” Journal of Neuropathology and Experimental Neurology, vol. 52, no. 3, pp. 183–191, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Baba, S. Nakajo, P.-H. Tu et al., “Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies,” American Journal of Pathology, vol. 152, no. 4, pp. 879–884, 1998. View at Google Scholar · View at Scopus
  3. M. J. Volles and P. T. Lansbury Jr., “Zeroing in on the pathogenic form of α-Synuclein and its mechanism of neurotoxicity in Parkinson's disease,” Biochemistry, vol. 42, no. 26, pp. 7871–7878, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Zhou, J. B. Milder, and C. R. Freed, “Transgenic mice overexpressing tyrosine-to-cysteine mutant human α-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease,” The Journal of Biological Chemistry, vol. 283, no. 15, pp. 9863–9870, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Colla, P. H. Jensen, O. Pletnikova, J. C. Troncoso, C. Glabe, and M. K. Lee, “Accumulation of toxic α-synuclein oligomer within endoplasmic reticulum occurs in α-synucleinopathy in vivo,” Journal of Neuroscience, vol. 32, no. 10, pp. 3301–3305, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. W. W. Smith, R. L. Margolis, X. Li et al., “α-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells,” Journal of Neuroscience, vol. 25, no. 23, pp. 5544–5552, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. T. Bartels, J. G. Choi, and D. J. Selkoe, “α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation,” Nature, vol. 477, no. 7362, pp. 107–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. C. L. Kragh, L. B. Lund, F. Febbraro et al., “α-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells,” Journal of Biological Chemistry, vol. 284, no. 15, pp. 10211–10222, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Zhou, M. Broe, Y. Huang et al., “Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease,” Acta Neuropathologica, vol. 121, no. 6, pp. 695–704, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Arawaka, M. Wada, S. Goto et al., “The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's disease,” Journal of Neuroscience, vol. 26, no. 36, pp. 9227–9238, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. K. J. Inglis, D. Chereau, E. F. Brigham et al., “Polo-like kinase 2 (PLK2) phosphorylates α-synuclein at serine 129 in central nervous system,” The Journal of Biological Chemistry, vol. 284, no. 5, pp. 2598–2602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Bergeron, R. Motter, P. Tanaka et al., “In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain,” Neuroscience, vol. 256, pp. 72–82, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. K.-W. Lee, W. Chen, E. Junn et al., “Enhanced phosphatase activity attenuates α-synucleinopathy in a mouse model,” Journal of Neuroscience, vol. 31, no. 19, pp. 6963–6971, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. B. I. Pérez-Revuelta, M. M. Hettich, A. Ciociaro et al., “Metformin lowers Ser-129 phosphorylated α-synuclein levels via mTOR-dependent protein phosphatase 2A activation,” Cell Death and Disease, vol. 5, no. 5, Article ID e1209, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. G. A. Grabowski, “Phenotype, diagnosis, and treatment of Gaucher's disease,” The Lancet, vol. 372, no. 9645, pp. 1263–1271, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. K. E. Murphy, A. M. Gysbers, S. K. Abbott et al., “Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease,” Brain, vol. 137, no. 3, pp. 834–848, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Galadari, A. Hago, and M. Patel, “Effects of cations on ceramide-activated protein phosphatase 2A,” Experimental and Molecular Medicine, vol. 33, no. 4, pp. 240–244, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Samii, J. G. Nutt, and B. R. Ransom, “Parkinson's disease,” The Lancet, vol. 363, no. 9423, pp. 1783–1793, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Braak, U. Rüb, W. P. Gai, and K. Del Tredici, “Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen,” Journal of Neural Transmission, vol. 110, no. 5, pp. 517–536, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. K. R. Chaudhuri, D. G. Healy, and A. H. Schapira, “Non-motor symptoms of Parkinson's disease: diagnosis and management,” Lancet Neurology, vol. 8, no. 5, pp. 464–474, 2009. View at Publisher · View at Google Scholar
  21. K. Wakabayashi and H. Takahashi, “Neuropathology of autonomic nervous system in Parkinson's disease,” European Neurology, vol. 38, no. 2, pp. 2–7, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. H. Braak, K. Del Tredici, U. Rüb, R. A. I. De Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson's disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Masuda-Suzukake, T. Nonaka, M. Hosokawa et al., “Prion-like spreading of pathological α-synuclein in brain,” Brain, vol. 136, no. 4, pp. 1128–1138, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Recasens and B. Dehay, “Alpha-synuclein spreading in Parkinson’s disease,” Frontiers in Neuroanatomy, vol. 8, article 159, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. E. C. Freundt, N. Maynard, E. K. Clancy et al., “Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport,” Annals of Neurology, vol. 72, no. 4, pp. 517–524, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. K. M. Danzer, L. R. Kranich, W. P. Ruf et al., “Exosomal cell-to-cell transmission of alpha synuclein oligomers,” Molecular Neurodegeneration, vol. 7, no. 1, article 42, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Lopes da Fonseca, A. Villar-Piqué, and T. Outeiro, “The interplay between alpha-synuclein clearance and spreading,” Biomolecules, vol. 5, no. 2, pp. 435–471, 2015. View at Publisher · View at Google Scholar
  28. H.-J. Lee, S. Patel, and S.-J. Lee, “Intravesicular localization and exocytosis of α-synuclein and its aggregates,” Journal of Neuroscience, vol. 25, no. 25, pp. 6016–6024, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. O. M. A. El-Agnaf, S. A. Salem, K. E. Paleologou et al., “Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease,” The FASEB Journal, vol. 20, no. 3, pp. 419–425, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. C. R. Pacheco, C. N. Morales, A. E. Ramírez et al., “Extracellular α-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane,” Journal of Neurochemistry, vol. 132, no. 6, pp. 731–741, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Jang, H.-J. Lee, J.-E. Suk, J.-W. Jung, K.-P. Kim, and S.-J. Lee, “Non-classical exocytosis of α-synuclein is sensitive to folding states and promoted under stress conditions,” Journal of Neurochemistry, vol. 113, no. 5, pp. 1263–1274, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Fahn, R. L. Elton, and Members of the UPDRS Committee, “Unified Parkinson's disease rating scale,” in Recent Developments in Parkinson's Disease, S. Fahn, C. D. Marsden, M. Goldstein et al., Eds., pp. 153–163, McMillan Health Care, New Jersey, NJ, USA, 1983. View at Google Scholar
  33. S. Yu, T. Zhao, M. Guo et al., “Hypoxic preconditioning up-regulates glucose transport activity and glucose transporter (GLUT1 and GLUT3) gene expression after acute anoxic exposure in the cultured rat hippocampal neurons and astrocytes,” Brain Research, vol. 1211, pp. 22–29, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. P. G. Foulds, J. D. Mitchell, A. Parker et al., “Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease,” The FASEB Journal, vol. 25, no. 12, pp. 4127–4137, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Liu, M. Chen, N. Mi et al., “Increased oligomerization and phosphorylation of α-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains,” Neurobiology of Aging, vol. 36, no. 9, pp. 2649–2659, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. Z. Qi, W. Yang, Y. Liu et al., “Loss of PINK1 function decreases PP2A activity and promotes autophagy in dopaminergic cells and a murine model,” Neurochemistry International, vol. 59, no. 5, pp. 572–581, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. P. Dietrich, H. J. Rideout, Q. Wang, and L. Stefanis, “Lack of p53 delays apoptosis, but increases ubiquitinated inclusions, in proteasomal inhibitor-treated cultured cortical neurons,” Molecular and Cellular Neuroscience, vol. 24, no. 2, pp. 430–441, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. H. J. Rideout, P. Dietrich, Q. Wang, W. T. Dauer, and L. Stefanis, “α-synuclein is required for the fibrillar nature of ubiquitinated inclusions induced by proteasomal inhibition in primary neurons,” The Journal of Biological Chemistry, vol. 279, no. 45, pp. 46915–46920, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. E. Emmanouilidou, K. Melachroinou, T. Roumeliotis et al., “Cell-produced α-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival,” Journal of Neuroscience, vol. 30, no. 20, pp. 6838–6851, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. C. L. L. Pham and R. Cappai, “The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding,” Bioscience Reports, vol. 33, no. 5, Article ID e00074, pp. 807–814, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. K. M. Danzer, D. Haasen, A. R. Karow et al., “Different species of α-synuclein oligomers induce calcium influx and seeding,” Journal of Neuroscience, vol. 27, no. 34, pp. 9220–9232, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Prots, V. Veber, S. Brey et al., “α-synuclein oligomers impair neuronal microtubule-kinesin interplay,” Journal of Biological Chemistry, vol. 288, no. 30, pp. 21742–21754, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. M. K. Jain and R. Bhat, “Modulation of human α-synuclein aggregation by a combined effect of calcium and dopamine,” Neurobiology of Disease, vol. 63, pp. 115–128, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. J. R. Mazzulli, Y.-H. Xu, Y. Sun et al., “Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies,” Cell, vol. 146, no. 1, pp. 37–52, 2011. View at Publisher · View at Google Scholar · View at Scopus